scholarly journals Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE

2020 ◽  
Vol 10 (5) ◽  
pp. 309-323 ◽  
Author(s):  
Jason Aldred ◽  
Marieta Anca-Herschkovitsch ◽  
Angelo Antonini ◽  
Ovidiu Bajenaru ◽  
Lars Bergmann ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Interim Analysis ◽  
Clinical Trial Registration ◽  
Screening Criteria ◽  
Advanced Parkinson’S Disease ◽  
Troublesome Dyskinesia ◽  
Treatment Safety ◽  
Clinician Assessment

Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. Clinical Trial Registration: NCT02611713 ( ClinicalTrials.gov )

Long term follow-up in advanced Parkinson’s disease treated with DBS of the subthalamic nucleus

2021 ◽  
Author(s):  
Maria Antonietta Volonté ◽  
Giacomo Clarizio ◽  
Sebastiano Galantucci ◽  
Pietro Giuseppe Scamarcia ◽  
Rosalinda Cardamone ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subthalamic Nucleus ◽  
Advanced Parkinson’S Disease ◽  
Long Term Follow Up

Risperidone in levodopa-induced psychosis in advanced parkinson's disease: An open-label, long-term study

1997 ◽  
Vol 12 (4) ◽  
pp. 610-612 ◽  
Author(s):  
Giuseppe Meco ◽  
Andrea Alessandri ◽  
Patrizia Giustini ◽  
Vincenzo Bonifati
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Open Label ◽  
Term Study ◽  
Advanced Parkinson’S Disease ◽  
Long Term Study

scholarly journals PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study

BMC Neurology ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Simone Simoni ◽  
Pasquale Nigro ◽  
Marta Filidei ◽  
Giulia Cappelletti ◽  
Federico Paolini Paoletti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Retrospective Study ◽  
Protective Factor ◽  
T Test ◽  
Advanced Parkinson’S Disease ◽  
Peristomal Complications ◽  
Duodenal Levodopa Infusion ◽  
Complications And Mortality

Abstract Background Reducing percutaneous endoscopic gastrostomies with jejunal extension tubes (PEG-J) related complications is vital to the long-term preservation of duodenal levodopa infusion (DLI) in advanced Parkinson’s disease (APD). Here, we provide data on the frequency of complications for both the standard “pull” and the non-endoscopic, radiologic assisted, “push” replacement PEG-J techniques in APD. Methods We retrospectively identified all patients treated with DLI from October 2009 to January 2020 at the Movement Disorders Center. Patients features and demographics, PEG-J procedures, causes for any discontinuation, reported complications and mortality were collected. In this cohort, PEG-J replacements were performed using the standard “pull” procedure or the radiologic assisted “push” method. Descriptive statistical analysis, t-test and paired t-test with False Discovery Rate correction was performed. Results This retrospective study included 30 APD patients [median age 72 ± 5.6 years; mean disease duration 17.2 + 5.7 years]. Mean treatment duration was 35.6 (30.6) months. Overall, 156 PEG-J procedures were performed, and Nineteen patients (63.3%) had a total of 185 reported complications, 85 of which were peristomal complications. 17 (56.6%) underwent 100 replacement procedures due to complications. The most commonly reported complication for replacement was J-tube dislocation (36%). One patient discontinued treatment after 6 months, due to peripheral neuropathy. Six patients died for causes not related to DLI. PEG-J replacements performed with the “push” method had a higher turnover (5.6 vs. 7.6 mo.), but fewer reported complications (67 vs. 75%). Conclusion The overall rate of complications was lower for “push” technique. This result might have been due to a higher replacement turnover that acted as a protective factor.

scholarly journals A Longitudinal Randomized Controlled Trial Protocol to Evaluate the Effects of Wuqinxi on Dynamic Functional Connectivity in Parkinson’s Disease Patients

2021 ◽  
Vol 15 ◽  
Author(s):  
Yuting Li ◽  
Lanlan Zhang ◽  
Yin Wu ◽  
Jian Zhang ◽  
Ke Liu
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Connectivity ◽  
Controlled Trial ◽  
Neural Mechanisms ◽  
Motor Symptoms ◽  
Clinical Trial Registration ◽  
Dynamic Functional Connectivity ◽  
And Gender

Background: Parkinson’s disease (PD) is a neurodegenerative movement disease that includes non-motor symptoms such as cognitive impairment. Long-term mind-body exercise has been shown to improve cognitive ability in PD patients, but the methods of assessment and intervention were inconsistent across studies. Wuqinxi is a mind-body exercise that is easy to learn, has few physical and cognitive demands, and is recommended for PD patients. Dynamic functional connectivity (DFC) has been associated with cognitive alterations in PD patients, but no studies have yet explored the effects of Wuqinxi on this association. The current protocol is designed to measure the effects of long-term Wuqinxi intervention on cognition in PD patients, and explore the underlying neural mechanisms through DFC.Methods: A long-term single-blind, randomized trial will be conducted. PD patients and age- and gender-matched HC will be recruited; PD patients will be randomly assigned to either Wuqinxi or balance groups, and HC will all receive health education. The Wuqinxi group will receive a 90-min session of Wuqinxi intervention three times a week for 24 weeks, while the balance group will receive balance exercise instruction on the same schedule. Primary outcomes will include assessment of cognitive domains and dynamic temporal characteristics of functional connectivity. Secondary outcomes will include severity of motor symptoms, mobility, balance, and emotional state. Assessments will be conducted at baseline, at the end of 24 weeks of intervention, and 12 weeks after interventions have ended.Discussion: This study will provide evidence to the effects of Wuqinxi exercise on cognitive improvements in PD patients from the perspective of DFC, and will contribute to the understanding of neural mechanisms underlying cognitive enhancement through Wuqinxi practice.Clinical Trial Registration:www.chictr.org.cn, identifier ChiCTR2000038517.

scholarly journals Bromocriptine in the Long-Term Management of Advanced Parkinson’s Disease

1983 ◽  
Vol 10 (2) ◽  
pp. 86-90 ◽  
Author(s):  
J. David Grimes ◽  
Mohamed N. Hassan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dosage Adjustment ◽  
Peak Effect ◽  
Advanced Parkinson’S Disease ◽  
Sustained Improvement ◽  
Main Adverse Effect ◽  
Late Withdrawal ◽  
Term Benefit

SUMMARY:Thirty-seven patients with advanced Parkinson’s disease who initially tolerated, and responded to bromocriptine therapy were followed for 12 to 50 (mean 28) months. Using a method of gradual increase of bromocriptine, with concomitant levodopa reduction, the peak effect of the drug was apparent by three months, at which time the mean daily dose of bromocriptine was 23.9 mg and Sinemet (levodopa + carbidopa) had been reduced by 34 percent.Eight patients had sustained improvement without further drug changes for an average of 29 (range 14–50) months. After periods of improvement varying between 3 and 30 months, 29 patients had a fall-off from peak effect. Peak effect was regained in 21 of these 29 patients for an average of 16 additional months by initially increasing bromocriptine or Sinemet, or by eventually increasing both drugs. The main adverse effect was a confusional state which necessitated late withdrawal of bromocriptine in four patients. The best results were in younger patients with end-of-dose deterioration and levodopa induced dyskinesias.With cautious introduction, and intermittent dosage adjustment, bromocriptine can be of long-term benefit to patients with advanced Parkinson’s disease. The majority of patients have a gradual late fall-off in effect which can frequently be reversed with dosage adjustment.

scholarly journals 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Belinda Cruse ◽  
Hugo Morales-Briceño ◽  
Florence C F Chang ◽  
Neil Mahant ◽  
Ainhi D Ha ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Advanced Parkinson’S Disease ◽  
Troublesome Dyskinesia
Sign in / Sign up

Export Citation Format

Share Document